Related Experiment Video
Updated: Aug 19, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Treatment of skin and soft tissue infections with imipenem/cilastatin
Abstract:
Ninety-eight adult patients with skin and soft tissue infections caused by a variety of bacterial pathogens were treated with imipenem/cilastatin (71), cefazolin (21), or moxalactam (six) at three medical centers. Favorable clinical responses were observed in 87 of the 90 evaluable cases (97 percent). Most etiologic pathogens were eradicated during treatment including five of seven which demonstrated in vitro resistance to the therapeutic agent. Strains that persisted during treatment were not associated with therapeutic failure except in one cefazolin-treated patient who was infected with Bacteroides fragilis. All three drugs were well tolerated and no specific patterns of adverse reactions were observed.
Insights
Imipenem/cilastatin, cefazolin, and moxalactam effectively treated skin infections in 97% of patients. These antibiotics eradicated most bacteria, even those resistant in lab tests, with good tolerability.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Skin and soft tissue infections (SSTIs) represent a significant clinical challenge.
- Evaluating the efficacy and tolerability of broad-spectrum antibiotics is crucial for managing SSTIs.
Purpose of the Study:
- To assess the clinical effectiveness and safety of imipenem/cilastatin, cefazolin, and moxalactam in treating adult patients with SSTIs.
- To determine the impact of in vitro antibiotic resistance on clinical outcomes.
Main Methods:
- A multicenter study involving 98 adult patients diagnosed with bacterial SSTIs.
- Patients were treated with imipenem/cilastatin (n=71), cefazolin (n=21), or moxalactam (n=6).
- Clinical response and pathogen eradication rates were evaluated.
Main Results:
- A high favorable clinical response rate of 97% (87/90 evaluable cases) was observed across all treatment groups.
- Most causative bacterial pathogens were eradicated, including strains showing in vitro resistance to the administered antibiotic.
- Adverse reactions were minimal and did not show specific patterns across the three agents.
Conclusions:
- Imipenem/cilastatin, cefazolin, and moxalactam are highly effective and well-tolerated treatments for bacterial SSTIs.
- These antibiotics demonstrate efficacy even against certain pathogens with in vitro resistance, highlighting their clinical utility.
- The study supports the use of these agents in managing a variety of SSTIs.
Related Concept Videos
Endocarditis IV: Nursing Management
Myocarditis III: Medical Management
Acute Pyelonephritis II: Diagnostic Studies and Management
Urine Studies II: Urine Culture and Sensitivity Test
Production of Antibiotics
Clinical Significance of Antibiotic Resistance

